14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends

Autoimmunity Reviews

Volumn 13, Issue 9, 2014, Pages 917-930

  Bertolaccini, Maria Laura ^a   Amengual, Olga ^b   Andreoli, Laura ^c,p   Atsumi, Tatsuya ^b   Chighizola, Cecilia B ^d,q   Forastiero, Ricardo ^e   de Groot, Philip ^f   Lakos, Gabriella ^g   Lambert, Marc ^h   Meroni, Pierluigi ^i,q   Ortel, Thomas L ^j   Petri, Michelle ^e   Rahman, Anisur ^k   Roubey, Robert ^l,r   Sciascia, Savino ^a   Snyder, Melissa ^m   Tebo, Anne E ⁿ   Tincani, Angela ^c,p   Willis, Rohan ^o  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b HOKKAIDO UNIVERSITY   (Japan)

^c UNIVERSITY OF BRESCIA   (Italy)

^d SPEDALI CIVILI   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

^f ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^g FAVALORO UNIVERSITY   (Argentina)

^h UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

ⁱ INOVA DIAGNOSTICS INC   (United States)

^j LILLE UNIVERSITY HOSPITAL   (France)

^k DUKE UNIVERSITY MEDICAL CENTER   (United States)

^l JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^m UNIVERSITY COLLEGE LONDON   (United Kingdom)

ⁿ UNIVERSITY OF NORTH CAROLINA   (United States)

^o UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^p MAYO CLINIC   (United States)

^q ARUP INSTITUTE FOR CLINICAL AND EXPERIMENTAL PATHOLOGY   (United States)

^r University of Texas Medical Branch School of Medicine   (United States)

more..

Author keywords

ACL; Antiprothrombin antibodies; Domain I; IgA; Lupus anticoagulant; Risk

Indexed keywords

ANTIBODY; CARDIOLIPIN ANTIBODY; LUPUS ANTICOAGULANT; PHOSPHATIDYLETHANOLAMINE ANTIBODY; PHOSPHATIDYLSERINE ANTIBODY; PHOSPHOLIPID ANTIBODY; PROTHROMBIN ANTIBODY; UNCLASSIFIED DRUG; AUTOANTIBODY; BETA2 GLYCOPROTEIN 1;

ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY TITER; ANTIPHOSPHOLIPID SYNDROME; CLINICAL LABORATORY; DIAGNOSTIC TEST; ENZYME LINKED IMMUNOSORBENT ASSAY; HEALTH CARE ORGANIZATION; HIGH RISK PATIENT; HUMAN; IMMUNOASSAY; INTERNATIONAL STANDARD UNIT; LABORATORY TEST; LIMIT OF DETECTION; MEDICAL SOCIETY; PRACTICE GUIDELINE; PREDICTIVE VALUE; REFERENCE VALUE; REVIEW; STANDARDIZATION; ADVISORY COMMITTEE; ANIMAL; IMMUNOLOGY; ORGANIZATION;

ADVISORY COMMITTEES; ANIMALS; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; AUTOANTIBODIES; BETA 2-GLYCOPROTEIN I; CONGRESSES AS TOPIC; HUMANS;

EID: 84922593999     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2014.05.001     Document Type: Review

References (155)

1. Miyakis S., Lockshin M.D., Atsumi T., Branch D.W., Brey R.L., Cervera R., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006, 4(2):295-306.
2. Bertolaccini M.L., Hughes G.R., Khamashta M.A. Revisiting antiphospholipid antibodies: from targeting phospholipids to phospholipid binding proteins. Clin Lab 2004, 50(11-12):653-665.
3. Pierangeli S.S., de Groot P.G., Dlott J., Favaloro E., Harris E.N., Lakos G., et al. 'Criteria' aPL tests: report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, Texas, April 2010. Lupus 2011, 20(2):182-190.
4. Bertolaccini M.L., Amengual O., Atsumi T., Binder W.L., de Laat B., Forastiero R., et al. 'Non-criteria' aPL tests: report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, TX, USA, April 2010. Lupus 2011, 20(2):191-205.
5. Harris R.P., Helfand M., Woolf S.H., Lohr K.N., Mulrow C.D., Teutsch S.M., et al. Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med 2001, 20(Suppl. 3):21-35.
6. Balshem H., Helfand M., Schunemann H.J., Oxman A.D., Kunz R., Brozek J., et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 2011, 64(4):401-406.
7. Guyatt G.H., Oxman A.D., Vist G.E., Kunz R., Falck-Ytter Y., Alonso-Coello P., et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008, 336(7650):924-926.
8. Lakos G., Favaloro E.J., Harris E.N., Meroni P.L., Tincani A., Wong R.C., et al. International consensus guidelines on anticardiolipin and anti-beta2-glycoprotein I testing: report from the 13th International Congress on Antiphospholipid Antibodies. Arthritis Rheum 2012, 64(1):1-10.
9. Pierangeli S.S., Favaloro E.J., Lakos G., Meroni P.L., Tincani A., Wong R.C., et al. Standards and reference materials for the anticardiolipin and anti-beta2glycoprotein I assays: a report of recommendations from the APL Task Force at the 13th International Congress on Antiphospholipid Antibodies. Clin Chim Acta 2012, 413(1-2):358-360.
10. Wong R.C., Favaloro E.J., Adelstein S., Baumgart K., Bird R., Brighton T.A., et al. Consensus guidelines on anti-beta 2 glycoprotein I testing and reporting. Pathology 2008, 40(1):58-63.
11. Keeling D., Mackie I., Moore G.W., Greer I.A., Greaves M. British Committee for Standards in H. Guidelines on the investigation and management of antiphospholipid syndrome. Br J Haematol 2012, 157(1):47-58.
12. Tincani A., Allegri F., Balestrieri G., Reber G., Sanmarco M., Meroni P., et al. Minimal requirements for antiphospholipid antibodies ELISAs proposed by the European Forum on antiphospholipid antibodies. Thromb Res 2004, 114(5-6):553-558.
13. CLSI Defining, Establishing, and Verifying Reference Intrevals in the Clinical Laboratory; Approved Guideline. CLSI document C28-A3c 2010, Clinical and Laboratory Standards Institute, Wayne, PA. Third edition.
14. Devreese K.M., Van Hoecke F. Anticardiolipin and anti-beta2glycoprotein-I antibody cut-off values in the diagnosis of antiphospholipid syndrome: more than calculating the in-house 99th percentiles, even for new automated assays. Thromb Res 2011, 128(6):598-600.
15. Ruffatti A., Olivieri S., Tonello M., Bortolati M., Bison E., Salvan E., et al. Influence of different IgG anticardiolipin antibody cut-off values on antiphospholipid syndrome classification. J Thromb Haemost 2008, 6(10):1693-1696.
16. Fangtham M., Petri M. 2013 update: Hopkins lupus cohort. Curr Rheumatol Rep 2013, 15(9):360.
17. Lockshin M.D., Kim M., Laskin C.A., Guerra M., Branch D.W., Merrill J., et al. Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies. Arthritis Rheum 2012, 64(7):2311-2318.
18. Reber G., Meijer P. In ECAT veritas?. Lupus 2012, 21(7):722-724.
19. Dembitzer F.R., Ledford Kraemer M.R., Meijer P., Peerschke E.I. Lupus anticoagulant testing: performance and practices by north american clinical laboratories. Am J Clin Pathol 2010, 134(5):764-773.
20. van Os G.M., de Laat B., Kamphuisen P.W., Meijers J.C., de Groot P.G. Detection of lupus anticoagulant in the presence of rivaroxaban using Taipan snake venom time. J Thromb Haemost 2011, 9(8):1657-1659.
21. Gharavi A.E., Harris E.N., Asherson R.A., Hughes G.R. Anticardiolipin antibodies: isotype distribution and phospholipid specificity. Ann Rheum Dis 1987, 46(1):1-6.
22. Weidmann C.E., Wallace D.J., Peter J.B., Knight P.J., Bear M.B., Klinenberg J.R. Studies of IgG, IgM and IgA antiphospholipid antibody isotypes in systemic lupus erythematosus. J Rheumatol 1988, 15(1):74-79.
23. Kalunian K.C., Peter J.B., Middlekauff H.R., Sayre J., Ando D.G., Mangotich M., et al. Clinical significance of a single test for anti-cardiolipin antibodies in patients with systemic lupus erythematosus. Am J Med 1988, 85(5):602-608.
24. Alarcon-Segovia D., Deleze M., Oria C.V., Sanchez-Guerrero J., Gomez-Pacheco L., Cabiedes J., et al. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients. Medicine (Baltimore) 1989, 68(6):353-365.
25. Molina J.F., Gutierrez-Urena S., Molina J., Uribe O., Richards S., De Ceulaer C., et al. Variability of anticardiolipin antibody isotype distribution in 3 geographic populations of patients with systemic lupus erythematosus. J Rheumatol 1997, 24(2):291-296.
26. Cucurull E., Gharavi A.E., Diri E., Mendez E., Kapoor D., Espinoza L.R. IgA anticardiolipin and anti-beta2-glycoprotein I are the most prevalent isotypes in African American patients with systemic lupus erythematosus. Am J Med Sci 1999, 318(1):55-60.
27. Tajima C., Suzuki Y., Mizushima Y., Ichikawa Y. Clinical significance of immunoglobulin A antiphospholipid antibodies: possible association with skin manifestations and small vessel vasculitis. J Rheumatol 1998, 25(9):1730-1736.
28. Lopez L.R., Santos M.E., Espinoza L.R., La Rosa F.G. Clinical significance of immunoglobulin A versus immunoglobulins G and M anti-cardiolipin antibodies in patients with systemic lupus erythematosus. Correlation with thrombosis, thrombocytopenia, and recurrent abortion. Am J Clin Pathol 1992, 98(4):449-454.
29. Hanly J.G., Hong C., Smith S., Fisk J.D. A prospective analysis of cognitive function and anticardiolipin antibodies in systemic lupus erythematosus. Arthritis Rheum 1999, 42(4):728-734.
30. Sebastiani G.D., Galeazzi M., Tincani A., Piette J.C., Font J., Allegri F., et al. Anticardiolipin and anti-beta2GPI antibodies in a large series of European patients with systemic lupus erythematosus. Prevalence and clinical associations. European Concerted Action on the Immunogenetics of SLE. Scand J Rheumatol 1999, 28(6):344-351.
31. Samarkos M., Davies K.A., Gordon C., Loizou S. Clinical significance of IgA anticardiolipin and anti-beta2-GP1 antibodies in patients with systemic lupus erythematosus and primary antiphospholipid syndrome. Clin Rheumatol 2006, 25(2):199-204.
32. Shen Y.M., Lee R., Frenkel E., Sarode R. IgA antiphospholipid antibodies are an independent risk factor for thromboses. Lupus 2008, 17(11):996-1003.
33. Akhter E., Shums Z., Norman G.L., Binder W., Fang H., Petri M. Utility of antiphosphatidylserine/prothrombin and IgA antiphospholipid assays in systemic lupus erythematosus. J Rheumatol 2013, 40(3):282-286.
34. Wong K.L., Liu H.W., Ho K., Chan K., Wong R. Anticardiolipin antibodies and lupus anticoagulant in Chinese patients with systemic lupus erythematosus. J Rheumatol 1991, 18(8):1187-1192.
35. Loizou S., Cofiner C., Weetman A.P., Walport M.J. Immunoglobulin class and IgG subclass distribution of anticardiolipin antibodies in patients with systemic lupus erythematosus and associated disorders. Clin Exp Immunol 1992, 90(3):434-439.
36. Merkel P.A., Chang Y., Pierangeli S.S., Convery K., Harris E.N., Polisson R.P. The prevalence and clinical associations of anticardiolipin antibodies in a large inception cohort of patients with connective tissue diseases. Am J Med 1996, 101(6):576-583.
37. Selva-O'Callaghan A., Ordi-Ros J., Monegal-Ferran F., Martinez N., Cortes-Hernandez F., Vilardell-Tarres M. IgA anticardiolipin antibodies-relation with other antiphospholipid antibodies and clinical significance. Thromb Haemost 1998, 79(2):282-285.
38. Fanopoulos D., Teodorescu M.R., Varga J., Teodorescu M. High frequency of abnormal levels of IgA anti-beta2-glycoprotein I antibodies in patients with systemic lupus erythematosus: relationship with antiphospholipid syndrome. J Rheumatol 1998, 25(4):675-680.
39. Lakos G., Kiss E., Regeczy N., Tarjan P., Soltesz P., Zeher M., et al. Isotype distribution and clinical relevance of anti-beta2-glycoprotein I (beta2-GPI) antibodies: importance of IgA isotype. Clin Exp Immunol 1999, 117(3):574-579.
40. Greco T.P., Amos M.D., Conti-Kelly A.M., Naranjo J.D., Ijdo J.W. Testing for the antiphospholipid syndrome: importance of IgA anti-beta 2-glycoprotein I. Lupus 2000, 9(1):33-41.
41. Spadaro A., Riccieri V., Terracina S., Rinaldi T., Taccari E., Zoppini A. Class specific rheumatoid factors and antiphospholipid syndrome in systemic lupus erythematosus. Lupus 2000, 9(1):56-60.
42. Shrivastava A., Dwivedi S., Aggarwal A., Misra R. Anti-cardiolipin and anti-beta2 glycoprotein I antibodies in Indian patients with systemic lupus erythematosus: association with the presence of seizures. Lupus 2001, 10(1):45-50.
43. Bertolaccini M.L., Atsumi T., Escudero-Contreras A., Khamashta M.A., Hughes G.R.V. The value of IgA antiphospholipid testing for the diagnosis of antiphospholipid (Hughes) syndrome in systemic lupus erythematosus. J Rheumatol 2001, 28(12):2637-2643.
44. Lee R.M., Branch D.W., Oshiro B.T., Rittenhouse L., Orcutt A., Silver R.M. IgA b2 Glycoprotein-I antibodies are elevated in women with unexplained recurrent spontaneous abortion and unexplained fetal death. J Autoimmun 2000, 15(2):A63. [abstract].
45. Carmo-Pereira S., Bertolaccini M.L., Escudero-Contreras A., Khamashta M.A., Hughes G.R. Value of IgA anticardiolipin and anti-beta(2)-glycoprotein I antibody testing in patients with pregnancy morbidity. Ann Rheum Dis 2003, 62(6):540-543.
46. Mehrani T., Petri M. Association of IgA Anti-beta2 glycoprotein I with clinical and laboratory manifestations of systemic lupus erythematosus. J Rheumatol 2011, 38(1):64-68.
47. Iverson G.M., von Muhlen C.A., Staub H.L., Lassen A.J., Binder W., Norman G.L. Patients with atherosclerotic syndrome, negative in anti-cardiolipin assays, make IgA autoantibodies that preferentially target domain 4 of beta2-GPI. J Autoimmun 2006, 27(4):266-271.
48. Yamada H., Tsutsumi A., Ichikawa K., Kato E.H., Koike T., Fujimoto S. IgA-class anti-beta2-glycoprotein I in women with unexplained recurrent spontaneous abortion. Arthritis Rheum 1999, 42(12):2727-2728.
49. Sweiss N.J., Bo R., Kapadia R., Manst D., Mahmood F., Adhikari T., et al. IgA anti-beta2-glycoprotein I autoantibodies are associated with an increased risk of thromboembolic events in patients with systemic lupus erythematosus. PLoS One 2010, 5(8):e12280.
50. Tsutsumi A., Matsuura E., Ichikawa K., Fujisaku A., Mukai M., Kobayashi S., et al. Antibodies to beta 2-glycoprotein I and clinical manifestations in patients with systemic lupus erythematosus. Arthritis Rheum 1996, 39(9):1466-1474.
51. Cucurull E., Espinoza L.R., Mendez E., Molina J.F., Molina J., Ordi-Ros J., et al. Anticardiolipin and anti-beta2glycoprotein-I antibodies in patients with systemic lupus erythematosus: comparison between Colombians and Spaniards. Lupus 1999, 8(2):134-141.
52. Lee R.M., Branch D.W., Silver R.M. Immunoglobulin A anti-beta2-glycoprotein antibodies in women who experience unexplained recurrent spontaneous abortion and unexplained fetal death. Am J Obstet Gynecol 2001, 185(3):748-753.
53. Lee S.S., Cho M.L., Joo Y.S., Kim W.U., Hong Y.S., Min J.K., et al. Isotypes of anti-beta2-glycoprotein I antibodies: association with thrombosis in patients with systemic lupus erythematosus. J Rheumatol 2001, 28(3):520-524.
54. Danowski A., Kickler T.S., Petri M. Anti-beta2-glycoprotein I: prevalence, clinical correlations, and importance of persistent positivity in patients with antiphospholipid syndrome and systemic lupus erythematosus. J Rheumatol 2006, 33(9):1775-1779.
55. Serrano A., Garcia F., Serrano M., Ramirez E., Alfaro F.J., Lora D., et al. IgA antibodies against beta2 glycoprotein I in hemodialysis patients are an independent risk factor for mortality. Kidney Int 2012, 81(12):1239-1244.
56. Murthy V., Willis R., Romay-Penabad Z., Ruiz-Limon P., Martinez-Martinez L.A., Jatwani S., et al. Value of isolated IgA anti-beta2-glycoprotein I positivity in the diagnosis of the antiphospholipid syndrome. Arthritis Rheum 2013, 65(12):3186-3193.
57. Samarkos M., Davies K., Loizou S. IgA class anti-beta2-glycoprotein I in patients with systemic lupus erythematosus [letter; comment]. J Rheumatol 1998, 25(11):2283-2284.
58. Guerin J., Casey E., Feighery C., Jackson J. Anti-Beta 2-glycoprotein I antibody isotype and IgG subclass in antiphospholipid syndrome patients. Autoimmunity 1999, 31(2):109-116.
59. Bruce I.N., Clark-Soloninka C.A., Spitzer K.A., Gladman D.D., Urowitz M.B., Laskin C.A. Prevalence of antibodies to beta2-glycoprotein I in systemic lupus erythematosus and their association with antiphospholipid antibody syndrome criteria: a single center study and literature review. J Rheumatol 2000, 27(12):2833-2837.
60. Martinez-Martinez L.A., Aguilar-Valenzuela R., Seif A., Binder W., Alarcon G.S., Pierangeli S. Do clinically relevant IgA anti-b2glycoprotein I (anti-b2GPI) antibodies bind to DIV/V of b2GPI?. Lupus 2010, 19(4):C130. [abstract].
61. Tebo A.E., Willis R., Jaskowski T., Magder M., Petri M., Pierangeli S.S., et al. Association of anti-beta 2 glycoprotein I antibodies in a large cohort of lupus patients. 14th International Congress on Anti-phospholipid Antibodies Rio de Janeiro, Brazil 2013, 229.
62. Tebo A.E., Willis R., Jaskowski T., Salmon J., Guerra M., Petri M., et al. Qualitative comparisons of anti-beta 2 glycoprotein immunoassays in two distinct cohorts of patients. 14th International Congress on Anti-phospholipid Antibodies Rio de Janeiro, Brazil 2013, P3-P22.
63. Ben Said M., Sfar I., Younes S., Chaker F., Bannour I., Boughamoura L., et al. Anti-beta 2 glycoprotein I autoantibodies and atherosclerosis in patients with ischemic stroke. J Thromb Haemost 2013, 11(Suppl. 2):991.
64. Willis R., Ruiz-Limon P., Romay-Penabad Z., Papalardo E., Carrera-Martin A.L., Pierangeli S.S. IgA anti-beta 2 glycoprotein I antibodies are pathogenic in a mouse model of antiphospholipid syndrome. J Thromb Haemost 2013, 11(Suppl. 2):179. [OC 41-3].
65. Tebo A.E., Jaskowski T.D., Phansalkar A.R., Litwin C.M., Branch D.W., Hill H.R. Diagnostic performance of phospholipid-specific assays for the evaluation of antiphospholipid syndrome. Am J Clin Pathol 2008, 129(6):870-875.
66. Tebo A.E., Jaskowski T.D., Hill H.R., Branch D.W. Clinical relevance of multiple antibody specificity testing in anti-phospholipid syndrome and recurrent pregnancy loss. Clin Exp Immunol 2008, 154(3):332-338.
67. Egerer K., Roggenbuck D., Buttner T., Lehmann B., Kohn A., von Landenberg P., et al. Single-step autoantibody profiling in antiphospholipid syndrome using a multi-line dot assay. Arthritis Res Ther 2011, 13(4):R118.
68. Sater M.S., Finan R.R., Abu-Hijleh F.M., Abu-Hijleh T.M., Almawi W.Y. Anti-phosphatidylserine, anti-cardiolipin, anti-beta2 glycoprotein I and anti-prothrombin antibodies in recurrent miscarriage at 8-12 gestational weeks. Eur J Obstet Gynecol Reprod Biol 2012, 163(2):170-174.
69. Merkel P.A., Chang Y., Pierangeli S.S., Harris E.N., Polisson R.P. Comparison between the standard anticardiolipin antibody test and a new phospholipid test in patients with connective tissue diseases. J Rheumatol 1999, 26(3):591-596.
70. Budd R., Harley E., Quarshie A., Henderson V., Harris E.N., Pierangeli S.S. A re-appraisal of the normal cut-off assignment for anticardiolipin IgM tests. J Thromb Haemost 2006, 4(10):2210-2214.
71. Suh-Lailam B.B., Cromar A., Davis K.W., Tebo A.E. APhL antibody ELISA as an alternative to anticardiolipin test for the diagnosis of antiphospholipid syndrome. Int J Clin Exp Pathol 2012, 5(3):210-215.
72. Harris E.N., Pierangeli S.S. A more specific assay for the detection of antiphospholipid. Clin Immunol Newsl 1995, 15:26-28.
73. Pierangeli S.S., Stewart M., Silva L.K., Harris E.N. An antiphospholipid wet workshop: 7th International Symposium on Antiphospholipid Antibodies. J Rheumatol 1998, 25(1):156-160.
74. Santiago M.B., Espinola R.G., Gharavi A.E., Harris E.N., Pierangeli S.S. Prevalence and detection of antiphospholipid antibodies in leptospirosis, syphilis and leishmaniasis using three different ELISA. Arthritis Rheum 2000, 43:S314.
75. Pierangeli S.S., Gharavi A.E., Harris E.N. Testing for antiphospholipid antibodies: problems and solutions. Clin Obstet Gynecol 2001, 44(1):48-57.
76. Grossi C., Borghi M.O., Willis R., Papalardo E., Pierangeli S.S., Meroni P. A more specific antiphospholipid immunoassay for the diagnosis of the antiphospholipid syndrome. 14th International Congress on Anti-phospholipid Antibodies Rio de Janeiro, Brazil. 2013, 322.
77. Day H.M., Thiagarajan P., Ahn C., Reveille J.D., Tinker K.F., Arnett F.C. Autoantibodies to beta2-glycoprotein I in systemic lupus erythematosus and primary antiphospholipid antibody syndrome: clinical correlations in comparison with other antiphospholipid antibody tests. J Rheumatol 1998, 25(4):667-674.
78. Harris E.N., Pierangeli S.S. 'Equivocal' antiphospholipid syndrome. J Autoimmun 2000, 15(2):81-85.
79. Seif A., Aguilar-Valenzuela R., Doan E., Alarcon G.S., Reveille J.D., Pierangeli S.S. Predictive value and clinical significance of various antiphospholipid (aPL) antibody tests in a multi-center SLE cohort. Lupus 2010, 19(4):535.
80. Willis R., Harris E.N., De Ceulaer K., Smikle M., Pierangeli S.S. Association of antiphospholipid antibodies detected in the aPHL Elisa with clinical manifestations of the antiphospholipid syndrome in two lupus cohorts. 14th International Congress on Anti-phospholipid Antibodies Rio de Janeiro, Brazil 2013, P3-P20.
81. Sciascia S., Sanna G., Murru V., Khamashta M.A., Bertolaccini M.L. The clinical value of testing for aPhL, a new Elisa kit with a unique phospholipid mixture in SLE patients. 14th International Congress on Anti-phospholipid Antibodies Rio de Janeiro, Brazil. 2013, P3-P29.
82. Sugi T., Katsunuma J., Izumi S., McIntyre J.A., Makino T. Prevalence and heterogeneity of antiphosphatidylethanolamine antibodies in patients with recurrent early pregnancy losses. Fertil Steril 1999, 71(6):1060-1065.
83. Matsubayashi H., Sugi T., Arai T., Kondo A., Suzuki T., Izumi S., et al. Different antiphospholipid antibody specificities are found in association with early repeated pregnancy loss versus recurrent IVF-failure patients. Am J Reprod Immunol 2001, 46(5):323-329.
84. Sugi T., Matsubayashi H., Inomo A., Dan L., Makino T. Antiphosphatidylethanolamine antibodies in recurrent early pregnancy loss and mid-to-late pregnancy loss. J Obstet Gynaecol Res 2004, 30(4):326-332.
85. Ulcova-Gallova Z., Krauz V., Novakova P., Milichovska L., Micanova Z., Bibkova K., et al. Anti-phospholipid antibodies against phosphatidylinositol, and phosphatidylserine are more significant in reproductive failure than antibodies against cardiolipin only. Am J Reprod Immunol 2005, 54(2):112-117.
86. Sanmarco M., Bardin N., Camoin L., Beziane A., Dignat-George F., Gamerre M., et al. Antigenic profile, prevalence, and clinical significance of antiphospholipid antibodies in women referred for in vitro fertilization. Ann N Y Acad Sci 2007, 1108:457-465.
87. Yamada H., Atsumi T., Kobashi G., Ota C., Kato E.H., Tsuruga N., et al. Antiphospholipid antibodies increase the risk of pregnancy-induced hypertension and adverse pregnancy outcomes. J Reprod Immunol 2009, 79(2):188-195.
88. Gris J.C., Quere I., Sanmarco M., Boutiere B., Mercier E., Amiral J., et al. Antiphospholipid and antiprotein syndromes in non-thrombotic, non-autoimmune women with unexplained recurrent primary early foetal loss. The Nimes Obstetricians and Haematologists Study-NOHA. Thromb Haemost 2000, 84(2):228-236.
89. Obayashi S., Ozaki Y., Sugi T., Kitaori T., Katano K., Suzuki S., et al. Antiphosphatidylethanolamine antibodies might not be an independent risk factor for further miscarriage in patients suffering recurrent pregnancy loss. J Reprod Immunol 2010, 85(2):186-192.
90. Balada E., Ordi-Ros J., Paredes F., Villarreal J., Mauri M., Vilardell-Tarres M. Antiphosphatidylethanolamine antibodies contribute to the diagnosis of antiphospholipid syndrome in patients with systemic lupus erythematosus. Scand J Rheumatol 2001, 30(4):235-241.
91. Bertolaccini M.L., Murru V., Sciascia S., Sanna G., Khamashta M.A. The clinical value of testing for antibodies to phosphatidylethanolamine (aPE) in patients with systemic lupus erythematosus (SLE). Thromb Res 2012, 130(6):914-918.
92. Akhter E., Fang H., Bardin N., Sanmarco M., Petri M. Antiphosphatidylethanolamineis not associated with thrombosis or pregnancy loss in systemic lupus ertythematosus. Arthritis Rheum 2012, 64(10):S741.
93. Velayuthaprabhu S., Matsubayashi H., Sugi T., Nakamura M., Ohnishi Y., Ogura T., et al. A unique preliminary study on placental apoptosis in mice with passive immunization of anti-phosphatidylethanolamine antibodies and anti-Factor XII antibodies. Am J Reprod Immunol 2011, 66(5):373-384.
94. Sokol D.K., McIntyre J.A., Short R.A., Gutt J., Wagenknecht D.R., Biller J., et al. Henoch-Schonlein purpura and stroke: antiphosphatidylethanolamine antibody in CSF and serum. Neurology 2000, 55(9):1379-1381.
95. Karmochkine M., Cacoub P., Piette J.C., Godeau P., Boffa M.C. Antiphosphatidylethanolamine antibody as the sole antiphospholipid antibody in systemic lupus erythematosus with thrombosis. Clin Exp Rheumatol 1992, 10:603-605.
96. Blaise S., Seinturier C., Imbert B., Beani J.C., Carpentier P.H. Thrombosis of legs arteries: imputability of anti-phosphatidylethanolamine antibodies?. Ann Dermatol Venereol 2005, 132(6-7 Pt 1):555-558.
97. Staub H.L., Harris E.N., Khamashta M.A., Savidge G., Chahade W.H., Hughes G.R.V. Antibody to phosphatidylethanolamine in a patient with lupus anticoagulant and thrombosis. Ann Rheum Dis 1989, 48(2):166-169.
98. Berard M., Chantome R., Marcelli A., Boffa M.C. Antiphosphatidylethanolamine antibody as the only antiphospholipid antibodies. I. Association with thrombosis and vascular cutaneous disease. J Rheumatol 1996, 23:1369-1374.
99. Gonzales-Portillo F., McIntyre J.A., Wagenknecht D.R., Williams L.S., Bruno A., Biller J. Spectrum of antiphospholipid antibodies (aPL) in patients with cerebrovascular disease. J Stroke Cerebrovasc Dis 2001, 10(5):222-226.
100. Sanmarco M., Gayet S., Alessi M.C., Audrain M., de Maistre E., Gris J.C., et al. Antiphosphatidylethanolamine antibodies are associated with an increased odds ratio for thrombosis. A multicenter study with the participation of the European Forum on antiphospholipid antibodies. Thromb Haemost 2007, 97(6):949-954.
101. Toschi V., Motta A., Castelli C., Gibelli S., Cimminiello C., Molaro G.L., et al. Prevalence and clinical significance of antiphospholipid antibodies to noncardiolipin antigens in systemic lupus erythematosus. Haemostasis 1993, 23(5):275-283.
102. Sciascia S., Sanna G., Murru V., Roccatello D., Khamashta M.A., Bertolaccini M.L. Anti-prothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome. A systematic review. Thromb Haemost 2014, 111(2):354-364.
103. Bertolaccini M.L., Atsumi T., Koike T., Hughes G.R., Khamashta M.A. Antiprothrombin antibodies detected in two different assay systems. Prevalence and clinical significance in systemic lupus erythematosus. Thromb Haemost 2005, 93(2):289-297.
104. Bertolaccini M.L., Gomez S., Pareja J.F., Theodoridou A., Sanna G., Hughes G.R., et al. Antiphospholipid antibody tests: spreading the net. Ann Rheum Dis 2005, 64(11):1639-1643.
105. Pregnolato F., Chighizola C.B., Encabo S., Shums Z., Norman G.L., Tripodi A., et al. Anti-phosphatidylserine/prothrombin antibodies: an additional diagnostic marker for APS?. Immunol Res 2013, 56(2-3):432-438.
106. Sciascia S., Murru V., Sanna G., Roccatello D., Khamashta M.A., Bertolaccini M.L. Clinical accuracy for diagnosis of antiphospholipid syndrome in systemic lupus erythematosus: evaluation of 23 possible combinations of antiphospholipid antibody specificities. J Thromb Haemost 2012, 10(12):2512-2518.
107. Sciascia S., Sanna G., Murru V., Khamashta M.A., Bertolaccini M.L. Validation of a commercially available kit to detect anti-phosphatidylserine/prothrombin antibodies in a cohort of systemic lupus erythematosus patients. Thromb Res 2014, 133(3):451-454.
108. Agmon-Levin N., Seguro L., Rosario C., Volkov I., Gatto M., Doria A., et al. A profile of antiphospholipid antibodies correlate with APS-related arterial thrombosis and CNS manifestations. 14th International Congress on Anti-phospholipid Antibodies Rio de Janeiro, Brazil. 2013, P3-P14.
109. Machaly S.A., Sharaf El-Din H.A. Clinical significance of antiphospholipid-binding protein co-factor antibodies in patients with antiphospholipid syndrome. Ann Rheum Dis 2010, 69(Suppl. 3):406.
110. Fabris M., Mansutti E., Quartuccio L., Peresan J., Curcio F., De Vita S., et al. Anti-prothrombin/phosphatidyl-serinecomplex autoantibodies in antiphospholipid syndrome: preliminary data using a new ELISA method. Ann Rheum Dis 2012, 71(Suppl. 3):678.
111. Zigon P., Perdan Pirkmajer K., Cucnik S., Ambrozic A., Tomsic M., Sodin Semrl S., et al. Anti-phosphatidylserine/prothrombin antibodies are associated with adverse pregnancy outcomes and could provide an additional marker for the diagnosis of APS patients. 14th International Congress on Anti-phospholipid Antibodies Rio de Janeiro, Brazil. 2013, P2-P17.
112. Willis R., Tebo A.E., Lakos G., Mahler M., Norman G.L., Branch D.W., et al. Anti-PS/PT (IgG) antibodies correlate with LAC and pregnancy complications in patients with antiphospholipid syndrome. 14th International Congress on Anti-phospholipid Antibodies Rio de Janeiro, Brazil 2013, P3-P21.
113. Bertolaccini M.L., Sciascia S., Murru V., Garcia-Fernandez C., Sanna G., Khamashta M.A. Antibodies to phosphatidylserine/prothrombin (aPS/PT) are an independent risk factor for thrombosis in patients with systemic lupus erythematosus (SLE). Arthritis Rheum 2011, 63(10):S9.
114. Miyara M., Arnaud L., Dufat L., Diemert M.C., Ankri A., Mathian A., et al. Presence of anti-phosphatidylserine/prothrombin antibodies with both IgG and IgM isotypes may be associated with the occurrence of catastrophic antiphospholipid syndrome in patients with antiphospholipid antibodies. Arthritis Rheum 2011, 63(10):S8.
115. Miyara M., Arnaud L., Dufat L., Diemert M.C., Ankri A., Mathian A., et al. Anti-phosphatidylserine/prothrombin antibody titers are strongly correlated with lupus anticoagulant assays in patients with antiphospholipid antibodies. Arthritis Rheum 2011, 63(10):S7.
116. Devreese K.M.J., Hoylaerts M.F. Autoantibodies against prothrombin and prothrombinphosphatidylserin complex: a diagnostic tool for the antiphospholipid syndrome?. J Thromb Haemost 2011, 9(Suppl. 2):167.
117. Shmeleva V., Smirnova O., Kobilyanskaya V., Papayan L. Haemostatic changes in coronary artery disease patients with hyperhomocysteinemia and anti-beta2glycoprotein-I and/or anti-prothrombin antibodies. J Theomb Haemost 2011, 9(Suppl. 2):165.
118. Tincani A., Morozzi G., Afeltra A., Alessandri C., Allegri F., Bistoni O., et al. Antiprothrombin antibodies: a comparative analysis of homemade and commercial methods. A collaborative study by the Forum Interdisciplinare per la Ricerca nelle Malattie Autoimmuni (FIRMA). Clin Exp Rheumatol 2007, 25(2):268-274.
119. Ioannou Y., Romay-Penabad Z., Pericleous C., Giles I., Papalardo E., Vargas G., et al. In vivo inhibition of antiphospholipid antibody-induced pathogenicity utilizing the antigenic target peptide domain I of beta2-glycoprotein I: proof of concept. J Thromb Haemost 2009, 7(5):833-842.
120. Pericleous C., Ruiz-Limon P., Romay-Penabad Z., Carrera-Martin A.L., Garza-Garcia A., Murfitt L., et al. Affinitty-purified antibodies directed to domain I of beta 2GPI are pathogenic in a mouse model of thrombosis. Arthritis Rheum 2012, 64:S740.
121. Agostinis C., Durigutto P., Sblattero D., Borghi M.O., Grossi C., Guida F., et al. A non complement-fixing antibody to beta2 glycoprotein I as a novel therapy to control abortions and thrombosis in antiphospholipid syndrome. Blood 2014, [Epub ahead of print 2014/03/20].
122. de Laat B., Wu X.X., van Lummel M., Derksen R.H., de Groot P.G., Rand J.H. Correlation between antiphospholipid antibodies that recognize domain I of beta2-glycoprotein I and a reduction in the anticoagulant activity of annexin A5. Blood 2007, 109(4):1490-1494.
123. de Laat B., Pengo V., Pabinger I., Musial J., Voskuyl A.E., Bultink I.E., et al. The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. J Thromb Haemost 2009, 7(11):1767-1773.
124. Levine A.B., Rand J.H., Wu X.X., Vega J., Ramon G., Lyman S.L., et al. Effect of Hydroxychloroquine (HCQ) on the Annexin A5 resistant assay (AnxA5-RA) in antiphospholipid antibody (aPL)-positive patients: preliminary results of an ongoing prospective study. Arthritis Rheum 2012, 64:S742.
125. Iverson G.M., Victoria E.J., Marquis D.M. Anti-beta2 glycoprotein I (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI. Proc Natl Acad Sci U S A 1998, 95(26):15542-15546.
126. Reddel S.W., Wang Y.X., Sheng Y.H., Krilis S.A. Epitope studies with anti-beta 2-glycoprotein I antibodies from autoantibody and immunized sources. J Autoimmun 2000, 15(2):91-96.
127. McNeeley P.A., Dlott J.S., Furie R.A., Jack R.M., Ortel T.L., Triplett D.A., et al. Beta2-glycoprotein I-dependent anticardiolipin antibodies preferentially bind the amino terminal domain of beta2-glycoprotein I. Thromb Haemost 2001, 86(2):590-595.
128. Iverson G.M., Reddel S., Victoria E.J., Cockerill K.A., Wang Y.X., Marti-Renom M.A., et al. Use of single point mutations in domain I of beta 2-glycoprotein I to determine fine antigenic specificity of antiphospholipid autoantibodies. J Immunol 2002, 169(12):7097-7103.
129. de Laat B., Derksen R.H., Urbanus R.T., de Groot P.G. IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood 2005, 105(4):1540-1545.
130. Wahezi D.M., Ilowite N.T., Wu X.X., Pelkmans L., Laat B., Schanberg L.E., et al. Annexin A5 anticoagulant activity in children with systemic lupus erythematosus and the association with antibodies to domain I of beta2-glycoprotein I. Lupus 2013, 22(7):702-711.
131. Ioannou Y., Giles I., Lambrianides A., Richardson C., Pearl L.H., Latchman D.S., et al. A novel expression system of domain I of human beta2 glycoprotein I in Escherichia coli. BMC Biotechnol 2006, 6:8.
132. Ioannou Y., Pericleous C., Giles I., Latchman D.S., Isenberg D.A., Rahman A. Binding of antiphospholipid antibodies to discontinuous epitopes on domain I of human beta(2)-glycoprotein I: mutation studies including residues R39 to R43. Arthritis Rheum 2007, 56(1):280-290.
133. Banzato A., Pozzi N., Frasson R., De Filippis V., Ruffatti A., Bison E., et al. Antibodies to Domain I of beta(2)Glycoprotein I are in close relation to patients risk categories in Antiphospholipid Syndrome (APS). Thromb Res 2011, 128(6):583-586.
134. Pengo V., Ruffatti A., Legnani C., Gresele P., Barcellona D., Erba N., et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost 2010, 8(2):237-242.
135. Andreoli L., Nalli C., Motta M., Norman G.L., Shums Z., Encabo S., et al. Anti-beta(2)-glycoprotein I IgG antibodies from 1-year-old healthy children born to mothers with systemic autoimmune diseases preferentially target domain 4/5: might it be the reason for their 'innocent' profile?. Ann Rheum Dis 2011, 70(2):380-383.
136. Andreoli L., Nalli C., Borghi M.O., Pregnolato F., Grossi C., Zanola A., et al. Domain I is the main specificity of anti-beta2GPI antibodies in systemic autoimmune diseases. 14th International Congress on Anti-phospholipid Antibodies Rio de Janeiro, Brazil 2013, 228.
137. Albesa R., Zohoury N., Pierangeli S.S., Iverson G.M., Norman G.L. Performance of a novel chemiluminescent test for detection of antibodies to β2GPI-domain I in patients with anti-phospholipid syndrome (APS). 8th International Congress on Autoimmunity Granada, Spain 2012.
138. Albesa R., Khamashta M., Shums Z., Zohoury N., Norman G.L., Mahler M. Antibodies (IgG) to domain I of beta 2 glycoprotein I measured by a novel chemiluminiscence assay. 8th International Congress on Autoimmunity Granada, Spain 2012.
139. Hollestelle M., van Schagen M., Kariman A., Pequeriaux N. Antibodies against domain I of beta2-glycoprotein I are a better predictor for the antiphospholipid syndrome than antibodies to the total protein. Congress of the international society of thrombosis and haemostasis Amsterdam, Netherlands 2013.
140. Zohoury N., Khamashta M., Atsumi T., Musial J., Watanabe H., Papp M., et al. Autoantibodies targeting Domain 1 of beta 2 glycoprotein I as promising marker in the diagnosis and risk stratification of the antiphospholipid syndrome. Arthritis Rheum 2013, 65:S4.
141. Agmon-Levin N., Seguro L., Rosario C., Mahler M., Gatto M., Tomer N., et al. Anti-beta2GPI-DI antibodies are a marker of thrombosis in APS. 14th International Congress on Anti-phospholipid Antibodies Rio de Janeiro, Brazil. 2013, 291.
142. Zuily S., de Laat B., Regnault V., Guillemin F., Kaminsky P., Albesa R., et al. Autoantibodies against domain I of beta2-glycoprotein indicate an increased risk for thrombosis in antiphospholipid patients. A prospective cohort study. 14th International Congress on Anti-phospholipid Antibodies Rio de Janeiro, Brazil 2013, 320.
143. Borghi M.O., Grossi C., Pregnolato F., Gerosa M., Andreoli L., Nalli C., et al. Anti-beta2 glycoprotein I-domain I autoantibodies: comparison between two methods of detection. 14th International Congress on Anti-phospholipid Antibodies Rio de Janeiro, Brazil. 2013, P3-P18.
144. Willis R., Mahler M., Pericleous C., Rahman A., Ioannou Y., Giles I., et al. Comparison of two anti beta2 glycoprotein I domain I autoantibody assays to aid in the diagnosis of the antiphospholipid syndrome. 14th International Congress on Anti-phospholipid Antibodies Rio de Janeiro, Brazil. 2013, P3-P30.
145. Tzoulaki I., Liberopoulos G., Ioannidis J.P. Assessment of claims of improved prediction beyond the Framingham risk score. JAMA 2009, 302(21):2345-2352.
146. Collins G.S., Moons K.G. Comparing risk prediction models. BMJ 2012, 344:e3186.
147. Sciascia S., Cosseddu D., Montaruli B., Kuzenko A., Bertero M.T. Risk Scale for the diagnosis of antiphospholipid syndrome. Ann Rheum Dis 2011, 70(8):1517-1518.
148. Otomo K., Atsumi T., Amengual O., Fujieda Y., Kato M., Oku K., et al. Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis Rheum 2012, 64(2):504-512.
149. Sciascia S., Sanna G., Murru V., Roccatello D., Khamashta M.A., Bertolaccini M.L. GAPSS: the Global Anti-Phospholipid Syndrome Score. Rheumatology (Oxford) 2013, 52(8):1397-1403.
150. Sciascia S., Bertolaccini M.L., Roccatello D., Khamashta M.A. Independent validation of the antiphospholipid score for the diagnosis of antiphospholipid syndrome. Ann Rheum Dis 2013, 72(1):142-143.
151. Sciascia S., Cuadrado M.J., Sanna G., Murru V., Roccatello D., Ateka-Barrutia O., et al. Prospective validation of the Global AntiPhospholpid Syndrome Score (GAPSS). Arthritis Rheum 2013, 65:S3.
152. Sciascia S., Sanna G., Murru V., Roccatello D., Khamashta M.A., Bertolaccini M.L. The Global AntiPhospholipid Syndrome Score (GAPSS) in primary APS. Arthritis Rheum 2013, 65:S1.
153. Cervera R., Rodriguez-Pinto I., Colafrancesco S., Conti F., Valesini G., Rosario C., et al. 14th International Congress on Antiphospholipid Antibodies Task Force Report on Catastrophic Antiphospholipid Syndrome. Autoimmun Rev 2014, 13(7):699-707.
154. de Jesus G.R., Agmon-Levin N., Andrade C.A., Andreoli L., Chighizola C.B., Porter T.F., et al. 14th International Congress on Antiphospholipid Antibodies Task Force report on obstetric antiphospholipid syndrome. Autoimmun Rev 2014, 13(8):795-813.
155. Erkan D., Aguiar C.L., Andrade D., Cohen H., Cuadrado M.J., Danowski A., et al. 14th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends. Autoimmun Rev 2014, 13(6):685-696.